Mendus to present multiple abstracts at ASH 2024, including survival update of ADVANCE II trial with lead program vididencel in AML
Keep reading
Mendus to present preclinical data supporting the combination potential of ilixadencel with the immune checkpoint inhibitor avelumab at SITC 2024
